임상약물유전학 검사와 적용: 진단검사의학 임상검사 지침 - 2부

키워드

참고문헌 (134)

1. Higashi MK, "Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy", JAMA, 287, pp.1690~1698 (2002)
2. Jacobs LG, "Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly", Clin Geriatr Med, 22, pp.17~32 (2006)
3. Rieder MJ, "Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose", N Engl J Med, 352, pp.2285~2293 (2005)
4. Shehab N, "National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin", Arch Intern Med, 170, pp.1926~1933 (2010)
5. "New labeling information for warfarin (marketed as Coumadin)"[URL]
6. Johnson JA, "Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing", Clin Pharmacol Ther, 90, pp.625~629 (2011)
7. Swen JJ, "Pharmacogenetics: from bench to byte--an update of guidelines", Clin Pharmacol Ther, 89, pp.662~673 (2011)
8. Roland Valdes Jr, "Laboratory analysis and application of pharmacogenetics to clinical practice. Laboratory medicine practice guideline", The national academy of clinical biochemistry, ~ (2010)
9. Ansell J, "Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)", Chest, 133, pp.160S~198S (2008)
10. Rost S, "Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2", Nature, 427, pp.537~541 (2004)
12. Lee CR, "Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data", Pharmacogenetics, 12, pp.251~263 (2002)
13. Limdi NA, "Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups", Blood, 115, pp.3827~3834 (2010)
14. Aithal GP, "Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications", Lancet, 353, pp.717~719 (1999)
15. Limdi NA, "Influence of CYP2C9 and VKORC1 1173C", T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin, 2008, pp.83, 312~321
16. Lindh JD, "Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis", Eur J Clin Pharmacol, 65, pp.365~375 (2009)
17. Ross KA, "Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements", J Hum Genet, 55, pp.582~589 (2010)
18. Wajih N, "Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1, the vitamin K 2,3-epoxide-reducing enzyme of the vitamin K cycle", J Biol Chem, 280, pp.31603~31607 (2005)
19. Yuan HY, "A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity", Hum Mol Genet, 14, pp.1745~1751 (2005)
20. Wadelius M, "Common VKORC1 and GGCX polymorphisms associated with warfarin dose", Pharmacogenomics J, 5, pp.262~270 (2005)
21. Gage BF, "Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin", Clin Pharmacol Ther, 84, pp.326~331 (2008)
22. Klein TE, "Estimation of the warfarin dose with clinical and pharmacogenetic data", N Engl J Med, 360, pp.753~764 (2009)
23. Relling MV, "CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network", Clin Pharmacol Ther, 89, pp.464~467 (2011)
24. Nunnelee JD, "Review of an Article: The international Warfarin Pharmacogenetics Consortium (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. NEJM 360 (8): 753-64", J Vasc Nurs, 27, pp.109~ (2009)
25. Nowak-Gottl U, "In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes", Blood, 116, pp.6101~6105 (2010)
26. Lenzini P, "Integration of genetic, clinical, and INR data to refine warfarin dosing", Clin Pharmacol Ther, 87, pp.572~578 (2010)
27. Lombardi R, "Measurement of warfarin in plasma by high performance liquid chromatography (HPLC) and its correlation with the international normalized ratio", Thromb Res, 111, pp.281~284 (2003)
28. Harrington DJ, "Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1", J Thromb Haemost, 6, pp.1663~1670 (2008)
29. Lee K, "How to use warfarin assays in patient management: analysis of 437 warfarin measurements in a clinical setting", Clin Pharmacokinet, 54, pp.517~525 (2015)
30. Scott SA, "Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update", Clin Pharmacol Ther, 94, pp.317~323 (2013)
31. Scott SA, "Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy", Clin Pharmacol Ther, 90, pp.328~332 (2011)
32. Mega JL, "Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis", JAMA, 304, pp.1821~1830 (2010)
33. Harmsze A, "Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation", Pharmacogenet Genomics, 20, pp.18~25 (2010)
34. Hwang SJ, "The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention", Thromb Res, 127, pp.23~28 (2011)
35. Xie X, "CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population", PLoS One, 8, pp.e59344~ (2013)
36. Jeong YH, "Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin", Circ Cardiovasc Interv, 4, pp.585~594 (2011)
37. 박경진, "Clinical, Pharmacokinetic, and Pharmacogenetic Determinants of Clopidogrel Resistance in Korean Patients with Acute Coronary Syndrome", Annals of Laboratory Medicine, 31(2), pp.91~94 (2011), 대한진단검사의학회
38. Lee JM, "Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans", Am J Cardiol, 104, pp.46~51 (2009)
39. Depta JP, "Antiplatelet therapy and proton pump inhibition: cause for concern?", Curr Opin Cardiol, 27, pp.642~650 (2012)
40. Lee SS, "Duplex pyrosequencing of the TPMT*3C and TPMT*6 alleles in Korean and Vietnamese populations", Clin Chim Acta, 398, pp.82~85 (2008)
41. Jun JB, "Thiopurine S-methyltransferase polymorphisms and the relationship between the mutant alleles and the adverse effects in systemic lupus erythematosus patients taking azathioprine", Clin Exp Rheumatol, 23, pp.873~876 (2005)
42. Cheon JH, "Allele frequency of thiopurine methyltransferase and inosine triphosphate pyrophosphatase gene polymorphisms in Korean patients with inflammatory bowel diseases", Hepatogastroenterology, 56, pp.421~423 (2009)
43. Kim JH, "Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study", J Clin Gastroenterol, 44, pp.e242~e248 (2010)
44. Schaeffeler E, "Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups", Clin Chem, 54, pp.1637~1647 (2008)
45. Kim H, "Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: a possible association between survival rate and ITPA polymorphism", PLoS One, 7, pp.e45558~ (2012)
46. Jeong Hoon Lee, "The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and Rabeprazole", Gut and Liver, 4(2), pp.201~206 (2010), 거트앤리버 발행위원회
47. Kim KA, "Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles", J Clin Pharm Ther, 35, pp.697~703 (2010)
48. Xie X, "Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial", Int J Cardiol, 168, pp.3736~3740 (2013)
49. Hicks JK, "Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants", Clin Pharmacol Ther, 93, pp.402~408 (2013)
50. Crews KR, "Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update", Clin Pharmacol Ther, 95, pp.376~382 (2014)
51. Crews KR, "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytoch-rome P450 2D6 (CYP2D6) genotype", Clin Pharmacol Ther, 91, pp.321~326 (2012)
52. 박형석, "Association between Genetic Polymorphisms of CYP2D6 and Outcomes in Breast Cancer Patients with Tamoxifen Treatment", Journal of Korean Medical Science, 26(8), pp.1007~1013 (2011), 대한의학회
53. Kim J, "Copy number variation and gene rearrangements in CYP2D6 genotyping using multiplex ligation-dependent probe amplification in Koreans", Pharmacogenomics, 13, pp.963~973 (2012)
54. Lee SJ, "Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans", Drug Metab Dispos, 37, pp.1464~1470 (2009)
55. Lee SY, "Sequence-based CYP2D6 genotyping in the Korean population", Ther Drug Monit, 28, pp.382~387 (2006)
56. Gaedigk A, "Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data", Pharmacogenetics, 9, pp.669~682 (1999)
57. Gaedigk A, "The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype", Clin Pharmacol Ther, 83, pp.234~242 (2008)
58. Hicks JK, "Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants", Clin Pharmacol Ther, 93, pp.402~408 (2013)
59. Crews KR, "Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update", Clin Pharmacol Ther, 95, pp.376~382 (2014)
60. Dezentje VO, "CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects", Breast Cancer Res Treat, 153, pp.583~590 (2015)
61. Irvin WJ Jr, "Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study", J Clin Oncol, 29, pp.3232~3239 (2011)
62. Kim SH, "Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis", Pharmacogenomics, 10, pp.1767~1779 (2009)
63. Bozok Cetintas V, "Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests", Tuberk Toraks, 56, pp.81~86 (2008)
64. Lee SW, "NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis", Int J Tuberc Lung Dis, 14, pp.622~626 (2010)
65. Cai Y, "Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis", PLoS One, 7, pp.e47769~ (2012)
66. Azuma J, "NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy", Eur J Clin Pharmacol, 69, pp.1091~1101 (2013)
67. Cho HJ, "Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis", Tuberculosis (Edinb), 87, pp.551~556 (2007)
68. "Human NAT2 Alleles (Haplotypes)"[URL]
69. Bertrand J, "Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia", J Infect Dis, 209, pp.399~408 (2014)
70. Lee SY, "Complete sequencing of a genetic polymorphism in NAT2 in the Korean population", Clin Chem, 48, pp.775~777 (2002)
71. Kang TS, "Comparison of genetic polymorphisms of the NAT2 gene between Korean and four other ethnic groups", J Clin Pharm Ther, 34, pp.709~718 (2009)
72. Lee KM, "N-acetyltransferase (NAT1, NAT2) and glutathione S-transferase (GSTM1, GSTT1) polymorphisms in breast cancer", Cancer Lett, 196, pp.179~186 (2003)
73. Fukino K, "Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients", J Toxicol Sci, 33, pp.187~195 (2008)
74. Peloquin CA, "Therapeutic drug monitoring in the treatment of tuberculosis", Drugs, 62, pp.2169~2183 (2002)
75. Um SW, "Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels", Int J Tuberc Lung Dis, 11, pp.972~978 (2007)
76. Han FF, "Associations between UGT1A1*6 or UGT1A1*6", *28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients, 2014, pp.73, 779~788
77. Cheng L, "UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity : a system review and meta-analysis in Asians", Cancer Chemother Pharmacol, 73, pp.551~560 (2014)
78. Innocenti F, "Pharmacogenetics of irinotecan : clinical perspectives on the utility of genotyping", Pharmacogenomics, 7, pp.1211~1221 (2006)
79. Sim SC, "Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects", Pharmacogenomics J, 13, pp.1~11 (2013)
80. Roshtkhari F, "Serological evaluation of relationship between viral pathogens (BHV-1, BVDV, BRSV, PI-3V, and Adeno3) and dairy calf pneumonia by indirect ELISA", Trop Anim Health Prod, 44, pp.1105~1110 (2012)
81. Kim KP, "A UGT1A1 *28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer", Cancer Chemother Pharmacol, 71, pp.1609~1617 (2013)
82. Relling MV, "Clinical pharmacogenetics implementation consortium gui-delines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update", Clin Pharmacol Ther, 93, pp.324~325 (2013)
83. Benkov K, "Role of thiopurine metabolite testing and thiopurine methyltransferase determination in pediatric IBD", J Pediatr Gastroenterol Nutr, 56, pp.333~340 (2013)
84. Lennard L, "The clinical pharmacology of 6-mercaptopurine", Eur J Clin Pharmacol, 43, pp.329~339 (1992)
85. Evans WE, "Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine", J Clin Oncol, 19, pp.2293~2301 (2001)
86. Appell ML, "Nomenclature for alleles of the thiopurine methyltransferase gene", Pharmacogenet Genomics, 23, pp.242~248 (2013)
87. Kim HY, "Complete sequence-based screening of TPMT variants in the Korean population", Pharmacogenet Genomics, 25, pp.143~146 (2015)
88. Lennard L, "Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia", Br J Clin Pharmacol, 76, pp.125~136 (2013)
89. Turner D, "Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines", J Pediatr Gastroenterol Nutr, 55, pp.340~361 (2012)
90. Lindeman NI, "Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology", J Mol Diagn, 15, pp.415~453 (2013)
91. "NCCN clinical practice guidelines in oncology. Colon Cancer. Version 2" (2014)[URL]
92. Wolff AC, "American Society of Clinical Oncology", College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer, 2007, pp.25, 118~145
93. Wolff AC, "Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology", College of American Pathologists clinical practice guideline update, 2013, pp.31, 3997~4013
94. Theriault RL, "Breast cancer, version 3.2013: featured updates to the NCCN guidelines", J Natl Compr Canc Netw, 11, pp.753~760 (2013)
95. Albanell J, "Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)", Clin Transl Oncol, 11, pp.363~375 (2009)
96. Bartlett JM, "HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods", J Clin Pathol, 64, pp.649~653 (2011)
97. Morton RF, "ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab-Clinical Implications in Colorectal Cancer", J Oncol Pract, 5, pp.71~72 (2009)
98. Van Cutsem E, "Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment", Ann Oncol, 21(Suppl 5), pp.v93~v97 (2010)
99. Becquemont L, "Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics", Pharmacogenomics, 12, pp.113~124 (2011)
100. Normanno N, "KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment", PLoS One, 6, pp.e29146~ (2011)
101. Garcia-Alfonso P, "Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)", Clin Transl Oncol, 14, pp.726~739 (2012)
102. De Roock W, "Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab", JAMA, 304, pp.1812~1820 (2010)
103. Tejpar S, "Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab", J Clin Oncol, 30, pp.3570~3577 (2012)
104. Neumann J, "Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer", Pathol Res Pract, 205, pp.858~862 (2009)
105. Cho HJ, "Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients", Pharmacogenomics, 8, pp.329~337 (2007)
106. Kim HS, "Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement", Pharmacogenet Genomics, 19, pp.103~112 (2009)
107. Choi JR, "Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients", J Hum Genet, 56, pp.290~295 (2011)
108. Cho HJ, "Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation", Clin Ther, 33, pp.1371~1380 (2011)
109. Sea Mi Park, "VKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean StrokePatients", 대한뇌졸중학회지, 15(2), pp.115~121 (2013), 대한뇌졸중학회[DOI]
110. 윤인경, "Effects of inflammatory cytokine gene polymorphisms on warfarin maintenance doses in Korean patients with mechanical cardiac valves", Archives of Pharmacal Research, 37(6), pp.752~759 (2014), 대한약학회
111. Ye C, "Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients", J Int Med Res, 42, pp.67~76 (2014)
112. Zhong SL, "The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement", Eur J Clin Pharmacol, 67, pp.581~590 (2011)
113. Wang TL, "Genetic factors contribute to patient-specific warfarin dose for Han Chinese", Clin Chim Acta, 396, pp.76~79 (2008)
114. Liang R, "Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients", J Thromb Thrombolysis, 34, pp.120~125 (2012)
115. Liu Y, "Comparative performance of warfarin pharmacogenetic algorithms in Chinese patients", Thromb Res, 130, pp.435~440 (2012)
116. Xu Q, "Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation", Thromb Haemost, 108, pp.1132~1140 (2012)
117. Zhang W, "Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism", Pharmacogenomics, 13, pp.309~321 (2012)
118. Larramendy-Gozalo C, "Genetic polymorphism of vitamin K epoxide reductase (VK-ORC1) 1173C>T in a Chinese and a Caucasian population", Basic Clin Pharmacol Toxicol, 98, pp.611~613 (2006)
119. Tomita H, "Patient factors against stable control of warfarin therapy for Japanese non-valvular atrial fibrillation patients", Thromb Res, 132, pp.537~542 (2013)
120. Cha PC, "Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese", Hum Mol Genet, 19, pp.4735~4744 (2010)
121. Yoshizawa M, "Effect of VKORC1-1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients", Thromb Res, 124, pp.161~166 (2009)
122. Obayashi K, "VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients", Clin Pharmacol Ther, 80, pp.169~178 (2006)
123. Mushiroda T, "Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients", J Hum Genet, 51, pp.249~253 (2006)
124. Strom CM, "Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory", Genet Med, 14, pp.95~100 (2012)
125. Goldstein JA, "Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations", Pharmacogenetics, 7, pp.59~64 (1997)
126. Lee SY, "Sequence-based CYP2D6 genotyping in the Korean population", Ther Drug Monit, 28, pp.382~387 (2006)
127. Meyer UA, "Pharmacogenetics - five decades of therapeutic lessons from genetic diversity", Nat Rev Genet, 5, pp.669~676 (2004)
128. Kaniwa N, "Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American", Drug Metab Dispos, 33, pp.458~465 (2005)
129. Ki CS, "Haplotype structure of the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene and its relationship to serum total bilirubin concentration in a male Korean population", Clin Chem, 49, pp.2078~2081 (2003)
130. Park WB, "Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency", Clin Infect Dis, 51, pp.101~106 (2010)
131. Choi YH, "A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity", Oncology, 82, pp.290~297 (2012)
132. Jo JC, "Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer", Br J Cancer, 106, pp.1591~1597 (2012)
133. Park SR, "Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results", Ann Oncol, 22, pp.890~896 (2011)
134. Lee SY, "Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application", J Pathol, 223, pp.15~27 (2011)

관련 논문AI추천